Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer-Reference-Cited by-同舟云学术

Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer

Published:2019-09-01 Issue:9 Volume:5 Page:1304
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Yu Nancy Y.¹,Iftimi Adina¹,Yau Christina²³,Tobin Nicholas P.⁴,van ’t Veer Laura⁵,Hoadley Katherine A.⁶,Benz Christopher C.³,Nordenskjöld Bo⁷,Fornander Tommy⁴,Stål Olle⁷⁸,Czene Kamila⁹,Esserman Laura J.²,Lindström Linda S.¹

Affiliation:

1. Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden

2. Department of Surgery, University of California, San Francisco, San Francisco

3. Buck Institute for Research on Aging, Novato, California

4. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

5. Department of Laboratory Medicine, University of California, San Francisco, San Francisco

6. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill

7. Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden

8. Department of Oncology, Linköping University, Linköping, Sweden

9. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2747879/jamaoncology_yu_2019_oi_190048.pdf

Reference22 articles.

1. Repeated observation of breast tumor subtypes in independent gene expression data sets.;Sørlie;Proc Natl Acad Sci U S A,2003

2. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.;Ades;J Clin Oncol,2014

3. St. Gallen 2013: brief preliminary summary of the consensus discussion.;Harbeck;Breast Care (Basel),2013

4. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group trials I to V.;Colleoni;J Clin Oncol,2016

5. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 Years.;Pan;N Engl J Med,2017

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EZH2 PROTACs target EZH2- and FOXM1-associated oncogenic nodes, suppressing breast cancer cell growth;Oncogene;2024-08-07

2. Targeting estrogen mediated CYP4F2/CYP4F11-20-HETE metabolic disorder decelerates tumorigenesis in ER+ breast cancer;Biochemistry and Biophysics Reports;2024-07

3. Comprehensive Young Age Breast Cancer registry from clinical, genomics, and patient-reported outcomes measured with 15 years follow-up: the CHARM cohort profile;Breast Cancer;2024-03-12

4. Exploring the Potential of Nanoparticles in the Treatment of Breast Cancer: Current Applications and Future Directions;Applied Sciences;2024-02-22

5. An estrogen-regulated long non-coding RNA NCALD promotes luminal breast cancer proliferation by activating GRHL2;Cancer Cell International;2024-01-30